Still fighting pharma’s misinfo campaign

“Falsehood flies, and the Truth comes limping after it.” —Jonathan Swift

The pushback against Eli Lilly’s misleading message continues. We’re referring, of course, to a letter the company has sent to various professional medical boards across the country, lying about the legal status of compounded GLP-1 drugs. It’s a scare tactic aimed at people whose perspectives (and mailing lists) matter.

Last week, Board President Gina Besteman told you how APC has sent letters to every state board of medicine, nursing, physician assistants, and naturopathic medicine, “that firmly corrects Big Pharma’s misrepresentations and shares what’s actually true about compounding.” 

Now we’ve expanded our ‘correction’ to every state board of pharmacy, explaining the law, calling out Lilly’s misrepresentations, and making a simple ask:

We urge the board to look critically at claims made in those submissions, to understand the facts about what federal and state law and policy say about compounded drugs, and to act with caution before supporting claims made not out of real concern for patient safety but in a brazen attempt to protect drugmaker profits.

As Gina said last week, it’s frustrating to have to spend our time countering misinformation being deliberately spread by a multinational company. Aren’t we all on the same side? We certainly think so.